(1999). MM: The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter. Cell Growth Differ
(1999). Morisaki T: Expression of MEF2 genes during human cardiac development. Tohoku J Exp Med
(2004). MS: Antagonism between DNA hypermethylation and enhancer-blocking activity at the H19 DMD is uncovered by CpG mutations. Nat Genet
(2004). MS: Role of H19 3' sequences in controlling H19 and Igf2 imprinting and expression. Genomics
(1994). Nasu K: WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood
(1992). ND: Zinc finger point mutations within the WT1 gene in Wilms tumor patients. Proc Natl Acad Sci USA
(2003). Oosterhuis JW: POU5F1 (OCT3/4) Identifies Cells with Pluripotent Potential in Human Germ Cell Tumors. Cancer Res
(2006). Orkin SH: A protein interaction network for pluripotency of embryonic stem cells. Nature
(1998). orphan nuclear receptor SF-1 in sex-specific gene expression. Cell
(2003). Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma. Cancer Science
(2004). Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Science
(2004). Overexpression of the Wilms' tumor gene WT1 in primary astrocytic tumors. Cancer Science
Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer.
(2006). Patsouris E: FGFR-2 and -3 play an important role in initial stages of oral oncogenesis. Anticancer Res
(1988). Pearson P: Molecular nature of genetic changes resulting in loss of heterozygosity of chromosome 11 in Wilms' tumours. Human Genetics
(1996). Perbal B: Regulation of nov by WT1: a potential role for nov in nephrogenesis. Oncogene
(2001). Pesole G: An algorithm for finding signals of unknown length in DNA sequences. Bioinformatics
(2006). Pesole G: MoD Tools: regulatory motif discovery in nucleotide sequences from co-regulated or homologous genes. Nucleic Acids Res
(2004). Pesole G: Weeder Web: discovery of transcription factor binding sites in a set of sequences from co-regulated genes. Nucleic Acids Res
(2000). Physical and functional interaction between the HCMV IE2 protein and the Wilms' tumor suppressor WT1. Biochem Biophys Res Commun
(2001). Polonsky KS: Molecular Mechanisms and Clinical Pathophysiology of Maturity-Onset Diabetes of the Young.
(1993). Polychronakos C: Parental genomic imprinting of the human IGF2 gene. Nat Genet
(1999). Probabilistic Outputs for Support Vector Machines and Comparisons to Regularized Likelihood Methods.
(2004). RA: Control of Pancreas and Liver Gene Expression by HNF Transcription Factors. Science
(2005). RA: Core transcriptional regulatory circuitry in human embryonic stem cells. Cell
(2005). Radvanyi F: Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet
(2005). Rajpert-De Meyts E: Stem cell pluripotency factor NANOG is expressed in human fetal gonocytes, testicular carcinoma in situ and germ cell tumours. Histopathology
(1995). Rauscher FJ 3rd, Ercolani L: LLC-PK1 cell growth is repressed by WT1 inhibition of G-protein alpha i2 protooncogene transcription.
(2008). Rauscher FJ 3rd: Repression of the insulin-like growth factor IIBiology Direct
(1992). Rauscher FJ 3rd: The Wilms' tumor gene product, WT1, represses transcription of the platelet-derived growth factor A-chain gene.
(1991). Rauscher FJ III: Transcriptional repression mediated by the WT1 Wilms tumor gene product. Science
(2006). Real FX: Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.
(2008). Reeve AE: Constitutional relaxation of insulin-like growth fac-Biology Direct
(2003). Regulatory sequence analysis tools.
(1995). Repression of the retinoic acid receptor-alpha gene by the Wilms' tumor suppressor gene product, wt1. Oncogene
(2004). RH: Defining the CREB Regulon: A Genome-Wide Analysis of Transcription Factor Regulatory Regions. Cell
(1997). RJ: Organization and Myogenic Restricted Expression of the Murine Serum Response Factor Gene. A Role for Autoregulation.
(1993). Roberts CT Jr: Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. Proc Natl Acad Sci USA
(1990). Role for the Wilms Tumor Gene in Genital Development. Proc Natl Acad Sci USA
(2002). Romashchenko AG: Transcription Regulatory Regions Database (TRDD): its status in 2002. Nucleic Acids Res
(1995). Roosen CB: An introduction to multivariate adaptive regression splines. Stat Methods Med Res
(1993). S e n s D , G a r v i n A : WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. Science
(2006). S: Inactivation of PU.1 in adult mice leads to the development of myeloid leukemia. Proc Natl Acad Sci USA
(2006). Saglio G: WT1 overexpression in acute myeloid leukemia and myelodysplastic syndromes. Methods in Molecular Medicine
(2006). Saqi MA: Predicting deleterious nsSNPs: an analysis of sequence and structural attributes.
(1994). Saunders G: Transcriptional regulation of the human Wilms' tumor gene (WT1). Cell type-specific enhancer and promiscuous promoter.
(1995). Saunders GF: Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Res
(1995). Sequence and structural requirements for high-affinity DNA binding by the WT1 gene product. Mol Cell Biol
(1990). Sequence logos: a new way to display consensus sequences. Nucleic Acids Res
(2007). Serum response factor binding sites differ in three human cell types. Genome Res